Navigation Links
Jazz Pharmaceuticals To Report Second Quarter 2013 Financial Results on August 6, 2013
Date:7/23/2013

DUBLIN, July 23, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its second quarter 2013 financial results on Tuesday, August 6, 2013, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to provide a business and financial update and discuss second quarter 2013 financial results.

Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.  A replay of the webcast will be archived on the website for one week.

Audio webcast/conference call:
U.S. Dial-In Number:  +1 877 280 4953
International Dial-In Number: +1 857 244 7310
Passcode: 10594339

A replay of the conference call will be available through August 13, 2013 and accessible through one of the following telephone numbers and entering the passcode:

Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number:  +1 617 801 6888
Passcode: 72340817

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs.  The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.  The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion and FazaClo® (clozapine, USP) HD.  Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division.  For further information, see www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
Breaking Medicine Technology:
(Date:8/22/2017)... AREA, CA (PRWEB) , ... August 22, 2017 ... ... an accessible luxurious collection of unique masks and serums that perfectly fuse the ... skin care advancements, at the 2017 Indie Beauty Expo on August 23rd & ...
(Date:8/22/2017)... Davis, California (PRWEB) , ... August 22, 2017 ... ... implies that the key to good health is as simple as eating healthy ... to food—whether it be storing fat, making insulin, or breaking apart carbohydrates—depends not ...
(Date:8/22/2017)... ... August 22, 2017 , ... Pivot ... addition of Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch ... firm’s national accounts, from assisting clients with initial vendor selection and pre-implementation planning ...
(Date:8/22/2017)... ... August 22, 2017 , ... GeBBS ... recently the availability of a new professional fee E/M leveling calculator tool. The ... to the healthcare industry. E/M coding is complex which supports the need for ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... Five Star Glass is new to the ... repair and replacement of auto glass for most makes and models, in Grand Prairie, TX, ... USA. , They have been a family owned business for the past 40 years ...
Breaking Medicine News(10 mins):